- Home
- HNVR vs XGN Comparison
HNVR vs XGN Comparison
Compare HNVR & XGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HNVR | XGN |
|---|---|---|
| Founded | 2008 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Commercial Banks | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 171.6M | 138.0M |
| IPO Year | 2022 | 2019 |
Fundamental Metrics
Financial Performance| Metric | HNVR | XGN |
|---|---|---|
| Price | $24.07 | $4.70 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 6 |
| Target Price | ★ $24.75 | $13.67 |
| AVG Volume (30 Days) | 14.5K | ★ 546.8K |
| Earning Date | 01-27-2026 | 03-10-2026 |
| Dividend Yield | ★ 1.70% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.52 | N/A |
| Revenue | ★ $68,038,000.00 | $63,599,000.00 |
| Revenue This Year | N/A | $21.40 |
| Revenue Next Year | $25.56 | $14.82 |
| P/E Ratio | $15.47 | ★ N/A |
| Revenue Growth | 10.44 | ★ 14.08 |
| 52 Week Low | $17.47 | $2.67 |
| 52 Week High | $27.00 | $12.23 |
Technical Indicators
Market Signals| Indicator | HNVR | XGN |
|---|---|---|
| Relative Strength Index (RSI) | 49.26 | 20.48 |
| Support Level | $21.51 | $4.75 |
| Resistance Level | $24.33 | $6.75 |
| Average True Range (ATR) | 0.66 | 0.44 |
| MACD | 0.00 | -0.07 |
| Stochastic Oscillator | 53.90 | 10.19 |
Price Performance
Historical ComparisonAbout HNVR Hanover Bancorp Inc.
Hanover Bancorp Inc is a United States-based banking company. It offers a full range of financial services and employs a complete suite of consumer and commercial banking products and services, including multi-family and commercial mortgages, residential loans, business loans, and lines of credit.
About XGN Exagen Inc.
Exagen Inc is a commercial-stage diagnostics company committed to addressing the unmet need for the accurate diagnosis and monitoring of patients affected by autoimmune rheumatic diseases. It currently markets ten testing products under its Avise brand to provide an accurate, timely, and differential diagnosis and to optimize the treatment of ARDs. It markets and sells solutions to community rheumatologists.